Iniciar sesión para ver los precios por organización y contrato.
Seleccione un Tamaño
Acerca de este artículo
Fórmula empírica (notación de Hill):
C9H19N3O6
Número CAS:
Peso molecular:
265.26
NACRES:
NA.26
PubChem Substance ID:
UNSPSC Code:
12352209
EC Number:
221-772-7
MDL number:
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarleServicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarleNombre del producto
L-Ornithine L-aspartate salt, powder
InChI key
IXUZXIMQZIMPSQ-ZBRNBAAYSA-N
InChI
1S/C5H12N2O2.C4H7NO4/c6-3-1-2-4(7)5(8)9;5-2(4(8)9)1-3(6)7/h4H,1-3,6-7H2,(H,8,9);2H,1,5H2,(H,6,7)(H,8,9)/t4-;2-/m00/s1
SMILES string
NCCC[C@H](N)C(O)=O.N[C@@H](CC(O)=O)C(O)=O
assay
≥98% (TLC)
form
powder
color
white to off-white
storage temp.
2-8°C
Quality Level
Categorías relacionadas
Biochem/physiol Actions
L-Ornithine L-aspartate is a metabolite of arginine degradation by arginase. It has been shown to reduce blood ammonia concentrations by increasing ammoniadetoxification in the muscle and reducing the severity of hepatic encephalopathy in cirrhosis.
Other Notes
Product of arginine degradation by arginase
Clase de almacenamiento
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Elija entre una de las versiones más recientes:
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Patrícia Coelho de Soárez et al.
Arquivos de gastroenterologia, 46(3), 241-247 (2009-11-18)
Experimental and clinical studies suggest that LOLA may have a favorable influence on hepatic encephalopathy due to the effect on the reduction of ammonia, and improvement of the symptoms and laboratory findings. To evaluate and to critically analyze the efficacy
Vibhu Vibhas Mittal et al.
European journal of gastroenterology & hepatology, 23(8), 725-732 (2011-06-08)
Minimal hepatic encephalopathy (MHE) impairs daily functioning and health-related quality of life (HRQoL). The modalities of treatment of MHE have not been adequately studied. To compare lactulose, probiotics, and L-ornithine L-aspartate (LOLA) in treatment of MHE and effect on HRQoL
Qian Jiang et al.
Journal of gastroenterology and hepatology, 24(1), 9-14 (2008-10-01)
Hepatic encephalopathy continues to be a major clinical problem and the current decade has not witnessed major therapeutic breakthroughs in this area. L-ornithine-l-aspartate (LOLA) is not frequently used as there are still some reservations about its benefits. The present study
Bin Zhang et al.
Bioresource technology, 284, 204-213 (2019-04-03)
l-ornithine, an important amino acid, is widely used in food and medicine industries. l-ornithine production mainly relies on microbial fermentation, which may not meet the industrial requirement owing to the poor fermentation ability of available strains. Herein, mscCG2 deletion, CgS9114_12202
Janus P Ong et al.
Clinical drug investigation, 31(4), 213-220 (2011-01-07)
Hepatic encephalopathy (HE) is a serious complication of cirrhosis. Clinical trials have consistently shown that L-ornithine-L-aspartate significantly improves HE symptoms. Health-related quality of life (HR-QOL) is impaired in HE patients and represents an important outcome measure for therapeutic intervention. The
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
Póngase en contacto con el Servicio técnico